Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by farmerjaneon Sep 07, 2012 11:08am
253 Views
Post# 20331774

Do not get your expectations up next week !

Do not get your expectations up next week !

I would not get to excited about new information in September. Amorfix presented at this conference in 2008, and I think it is just a front for another PP coming. What would really be interesting is how much of the Private placements under Gundels rein over the last two years, have gone to insiders and friends around them. It is evident to me that they have continued to keep information suppressed and delayed keeping the investment community on the sidelines. I am sure they have surpassed what the industry and Scientific community would provide as a reasonable time-frame for producing and testing their cancer therapuetic antibodies in animal models. The next   event after the next Private Placement will be the cmp's AGM on September 26 th. Last year the compensation committee composed of Sonnenrich, Couillard, Mekouar and Chertoff granted Gundel 560,000 options blowing what Adams used to get out of the water. Some of  the determing factors for compensation include, not limited to, individual performance, and the Corportation's performance. Nothing investors can do but wait it out !

Bullboard Posts